Nixon Peabody Trust Co. Sells 10,168 Shares of Johnson & Johnson $JNJ

Nixon Peabody Trust Co. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 25.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 29,987 shares of the company’s stock after selling 10,168 shares during the period. Nixon Peabody Trust Co.’s holdings in Johnson & Johnson were worth $4,581,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Nuveen LLC bought a new stake in Johnson & Johnson during the first quarter worth about $1,369,188,000. Pacer Advisors Inc. lifted its position in Johnson & Johnson by 1,382.0% in the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after buying an additional 2,825,626 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Kingstone Capital Partners Texas LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $401,420,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Johnson & Johnson by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 16,903,105 shares of the company’s stock worth $2,803,042,000 after acquiring an additional 2,129,612 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $195.19 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $196.00. The stock’s 50 day simple moving average is $185.46 and its two-hundred day simple moving average is $169.66. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a market cap of $470.27 billion, a price-to-earnings ratio of 18.84, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Scotiabank began coverage on Johnson & Johnson in a research report on Thursday. They set a “sector outperform” rating and a $230.00 price target on the stock. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $200.52.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.